ImpriMed
A precision-oncology service that tests live cancer cells against drugs and uses clinical data to predict which treatments may work best for each patient.
$10MSeries A2 bridge
ParticipantND
NAVER D2SF
Activity from announced rounds
Activity in this selectionUndisclosed
NAVER D2SF is NAVER’s startup investment organization, identified through official materials for ImpriMed and NdotLight.
Recorded funding activity
ImpriMed combines live-cell drug testing with clinical data. NdotLight generates simulation-ready 3D data, while F4GE structures factory information for industrial buyers. The organization retains its identity separately from NAVER Ventures and the parent.
Sources
- Rounds participated in
- 5
- Confirmed lead rounds
- 0 3 roles undisclosed
- New companies
- 5 First participation on record · 0 follow-on
- Funding in participating rounds
- $10M 1 disclosed · full round size, not this investor’s share
By stage
By primary sector
By country
Rounds
5 in this selectionSAZO
Cross-border shopping infrastructure connecting commerce platforms with payments, logistics and customs processes.
UndisclosedStrategic
Role not disclosedSoundable Health
Develops AI-powered acoustic analysis for clinical-grade diagnostics through everyday devices
UndisclosedUndisclosed
Role not disclosedNuvilab
Develops AI-powered nutrition analytics solution for healthcare
UndisclosedUndisclosed
Role not disclosedAnyware Robotics
Anyware Robotics builds mobile robots and control software for physically demanding material-handling work in warehouses and industrial facilities.
UndisclosedInvestment
Participant